---
title: "aTyr Pharma Q2 FY26 net loss narrows to $10.31 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295272329.md"
description: "aTyr Pharma reported a narrowed Q2 FY26 GAAP net loss of $10.31 million, down from $19.53 million year-over-year. Operating losses decreased to $10.88 million as R&D expenses fell significantly. The company holds $58.91 million in cash, projecting runway into late 2028. A restructuring plan involving a 60% workforce cut aims for $13 million in annual savings starting Q4 2026. Additionally, the Phase 3 efzofitimod protocol for pulmonary sarcoidosis was submitted to the FDA, with feedback expected by August."
datetime: "2026-08-07T20:02:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295272329.md)
  - [en](https://longbridge.com/en/news/295272329.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295272329.md)
generator: "portal-rs"
---

# aTyr Pharma Q2 FY26 net loss narrows to $10.31 million

-   aTyr Pharma posted a GAAP net loss attributable to shareholders of USD 10.31 million, narrowing from USD 19.53 million a year earlier; GAAP EPS improved to a loss of USD 0.11. \* GAAP operating loss tightened to USD 10.88 million from USD 20.31 million, while R&D expense fell to USD 6.75 million from USD 15.38 million. \* Cash, cash equivalents, restricted cash and investments ended June 30 at USD 58.91 million, with runway into late 2028 based on current operations. \* Restructuring includes a roughly 60% workforce cut, targeting about USD 13 million in annualized operating expense savings starting in Q4 2026. \* Protocol for a planned Phase 3 efzofitimod study in pulmonary sarcoidosis was submitted in June; FDA feedback is expected by end-August, while SSc-ILD Phase 2 topline data are due in Q1 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608071601PRIMZONEFULLFEED9805819) on August 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ATYR.US](https://longbridge.com/en/quote/ATYR.US.md)

## Related News & Research

- [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md)
- [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md)
- [Baker Hughes declares Q3 2026 dividend of R$ 0.81 per unit](https://longbridge.com/en/news/296392545.md)
- [Copenhagen Airports publishes H1 2026 interim report](https://longbridge.com/en/news/296606234.md)
- [Xcel Energy sets BRL 0.26 per unit distribution for payment Oct. 26, 2026](https://longbridge.com/en/news/296646864.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**